TY - JOUR
T1 - Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts
AU - Lijkwan, Maarten A.
AU - Cooke, David T.
AU - Martens, Jasper M.
AU - Kown, Murray H.
AU - Murata, Seiichiro
AU - Peterson, Shannon H.
AU - Hoyt, E. Grant
AU - Robbins, Robert C.
N1 - Funding Information:
Supported by The Netherlands Heart Foundation and The Ralph and Marian Falk Foundation for Cardiovascular Research (M.A.L.); the American Society of Transplantation Council’s fellowship (D.T.C.); and Roche Laboratories Surgical Scientist Scholarship from the American Society of Transplant Surgeons and the Ralph and Marian Falk Foundation for Cardiovascular Research (M.H.K.).
PY - 2005/4
Y1 - 2005/4
N2 - Background: Graft coronary artery disease (GCAD) limits allograft survival after cardiac transplantation. The objective of this study was to correlate GCAD with the level of immunosuppression in an established allogeneic rodent cardiac chronic rejection model to better understand the mechanisms of GCAD in this system. Methods: Donor PVG hearts were transplanted into the abdomen of ACI rats. Six recipient groups received either 10, 7.5 or 5 mg/kg/day of oral cyclosporine (CsA), for 90 (10mg/90d, 7.5mg/90d, 5mg/90d) or 10 days (10mg/10d, 7.5mg/10d, 5mg/10d; n = 10 all groups), and grafts procured on Day 90. GCAD was assessed by histology for percent luminal narrowing (%LN), percent affected vessels (%AV) and intima/media ratio (I/M ratio). Sections were stained for ED1-positive macrophages and MHC Class II-positive cells. Results: The 10mg/90d treatment group showed significantly reduced GCAD compared with the 5mg/10d treatment group (%LN = 4.3 ± 3.1% vs 39 ± 11.9%, p < 0.05). The 7.5mg/90d group had a reduced %LN and I/M ratio compared with the 5mg/10d group (%LN = 8.0 ± 3.5% vs 39 ± 11.9%, p < 0.05; I/M ratio = 0.06 ± 0.02 vs 0.41 ± 0.14, p < 0.05). There was a trend toward reduction of GCAD with both increasing the dose of CsA as well as the duration of treatment. Continuous treatment with CsA reduced perivascular macrophage and MHC II cell infiltration. Macrophage infiltrates correlated strongly with GCAD (R2 > 0.90, p < 0.01), and MHC II infiltrates showed a weak correlation, although not statistically significant (R2 > 0.56, p = NS). Conclusions: This study further defines the effect of cyclosporine on GCAD in this cardiac transplantation model. In this system, higher dose and longer duration of treatment with CsA markedly reduces macrophage and MHC II infiltration, correlating with diminished GCAD. However, increasing dose and duration of CsA did not completely eliminate the development of GCAD. Non-immunologic factors could contribute to this occurrence.
AB - Background: Graft coronary artery disease (GCAD) limits allograft survival after cardiac transplantation. The objective of this study was to correlate GCAD with the level of immunosuppression in an established allogeneic rodent cardiac chronic rejection model to better understand the mechanisms of GCAD in this system. Methods: Donor PVG hearts were transplanted into the abdomen of ACI rats. Six recipient groups received either 10, 7.5 or 5 mg/kg/day of oral cyclosporine (CsA), for 90 (10mg/90d, 7.5mg/90d, 5mg/90d) or 10 days (10mg/10d, 7.5mg/10d, 5mg/10d; n = 10 all groups), and grafts procured on Day 90. GCAD was assessed by histology for percent luminal narrowing (%LN), percent affected vessels (%AV) and intima/media ratio (I/M ratio). Sections were stained for ED1-positive macrophages and MHC Class II-positive cells. Results: The 10mg/90d treatment group showed significantly reduced GCAD compared with the 5mg/10d treatment group (%LN = 4.3 ± 3.1% vs 39 ± 11.9%, p < 0.05). The 7.5mg/90d group had a reduced %LN and I/M ratio compared with the 5mg/10d group (%LN = 8.0 ± 3.5% vs 39 ± 11.9%, p < 0.05; I/M ratio = 0.06 ± 0.02 vs 0.41 ± 0.14, p < 0.05). There was a trend toward reduction of GCAD with both increasing the dose of CsA as well as the duration of treatment. Continuous treatment with CsA reduced perivascular macrophage and MHC II cell infiltration. Macrophage infiltrates correlated strongly with GCAD (R2 > 0.90, p < 0.01), and MHC II infiltrates showed a weak correlation, although not statistically significant (R2 > 0.56, p = NS). Conclusions: This study further defines the effect of cyclosporine on GCAD in this cardiac transplantation model. In this system, higher dose and longer duration of treatment with CsA markedly reduces macrophage and MHC II infiltration, correlating with diminished GCAD. However, increasing dose and duration of CsA did not completely eliminate the development of GCAD. Non-immunologic factors could contribute to this occurrence.
UR - http://www.scopus.com/inward/record.url?scp=15544380871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15544380871&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2004.01.020
DO - 10.1016/j.healun.2004.01.020
M3 - Article
C2 - 15797746
AN - SCOPUS:15544380871
SN - 1053-2498
VL - 24
SP - 439
EP - 445
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 4
ER -